The company's test measures epigenetic alteration of two genes using Qiagen PCR methods, in order to detect signs of recurrence in colorectal cancer patients post-surgery.
The researchers concluded that each method has its own advantages and drawbacks depending on the sample being analyzed, cost restrictions, and the question.
The Singapore-based molecular diagnostics firm plans to use the funds for regulatory approvals and commercialization of its lead epigenetics-based test for breast cancer.
This month, GWG Life began sending out cheek swab kits to life insurance policy holders to analyze their saliva for epigenetic biomarkers developed at UCLA.
